After H.C. Wainwright and Guggenheim gave Global Blood Therapeutics (NASDAQ: GBT) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics yesterday and set a price target of $95. The company’s shares closed yesterday at $52.79.
According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.7% and a 37.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $89.14 average price target, representing a 68.9% upside. In a report issued on February 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $62.75 and a one-year low of $30.15. Currently, Global Blood Therapeutics has an average volume of 894K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
